It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microbial synthesis of nutraceutically and pharmaceutically interesting plant polyphenols represents a more environmentally friendly alternative to chemical synthesis or plant extraction. However, most polyphenols are cytotoxic for microorganisms as they are believed to negatively affect cell integrity and transport processes. To increase the production performance of engineered cell factories, strategies have to be developed to mitigate these detrimental effects. Here, we examine the accumulation of the stilbenoid resveratrol in the cell membrane and cell wall during its production using Corynebacterium glutamicum and uncover the membrane rigidifying effect of this stilbenoid experimentally and with molecular dynamics simulations. A screen of free fatty acid supplements identifies palmitelaidic acid and linoleic acid as suitable additives to attenuate resveratrol’s cytotoxic effects resulting in a three-fold higher product titer. This cost-effective approach to counteract membrane-damaging effects of product accumulation is transferable to the microbial production of other polyphenols and may represent an engineering target for other membrane-active bioproducts.
The inherent toxicity of the aromatic compounds to the chassis strain hampers further improvement of bioproduction. Here, the authors show that membrane rigidifying effect of resveratrol can be attenuated by exogenous supplementation of palmitelaidic acid or linoleic acid in fermentation of Corynebacterium glutamicum.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Forschungszentrum Jülich, Institute of Bio- and Geosciences, IBG-1: Biotechnology, Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X); RWTH Aachen University, Institute of Biotechnology, Aachen, Germany (GRID:grid.1957.a) (ISNI:0000 0001 0728 696X)
2 University of Groningen, Groningen Biomolecular Sciences and Biotechnology Institute, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
3 Aston University, College of Health and Life Sciences, Birmingham, UK (GRID:grid.7273.1) (ISNI:0000 0004 0376 4727)
4 Forschungszentrum Jülich, Institute for Information Processing, IBI-1: Molecular and Cellular Physiology, Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X)
5 Forschungszentrum Jülich, Institute of Bio- and Geosciences, IBG-1: Biotechnology, Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X)
6 Remembrane Srl, Imola, Italy (GRID:grid.4830.f)
7 Aston University, College of Health and Life Sciences, Birmingham, UK (GRID:grid.7273.1) (ISNI:0000 0004 0376 4727); University of Manchester, Manchester Institute of Biotechnology and Department of Chemistry, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407)
8 Remembrane Srl, Imola, Italy (GRID:grid.7273.1)